DDX41 and early-onset autosomal dominant Alzheimer disease: (ii) For Alzheimer’s disease characterized by the presence of amyloid β-polypeptide (Aβs), Actovegin can effectively mediate the inflammatory pathway caused by Aβs by increasing oxidative activation, which can improve cell apoptosis and protect the nervous system.